#sun-pharma
When the world's an oyster for Sun (Pharma)
Indian companies are increasingly making bold acquisitions abroad. Sun Pharma's deal signals a new era of deliberate empire-building. This shift from tentative deals to strategic bets is crucial for global relevance. Successful acquisitions require clear inte…
Sun Pharma shares rally 9% in two days after $12-bn Organon deal. Here's what Morgan Stanley, other brokerages say
Sun Pharmaceutical Industries' shares surged nearly 9% after announcing the $11.75 billion acquisition of Organon & Co., a global leader in women's health. The deal diversifies Sun Pharma's portfolio into women's health and biosimilars, with analysts from Mor…
Why Sun Pharma’s massive Organon buyout is winning over investors where Lupin, Biocon failed
Sun Pharma’s acquisition of Organon marks a pivot toward biosimilars, utilizing a cheap valuation and strong cash reserves to avoid the chronic post-merger stock slumps seen by Indian rivals.
Sun Pharma’s deal to buy Merck-spinoff Organon ticks the right box on acquisition cost if not R&D
Sun Pharma’s acquisition of US-based Organon looks like a financial bargain for the global scale and market access it offers. But the Indian drugmaker may need to look elsewhere for an R&D boost that could put it at the cutting edge of healthcare.
Sun's strong gravity helps India Inc's pull
Sun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies Sun Pharma's portfolio in critical areas like dermatology, oncology, and women’s health, while providing a gateway to new…
Sun Pharma Joins the Big Table With Organon Acquisition
Sun Pharma bought NJ-based Organon for $12 billion, in the largest overseas acquisition by any Indian pharma company.